Fig. 2From: Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumabAverage change from baseline central macular thickness (CMT) at each time point; CMT values are displayed in µm; M0: Baseline, M1: Month 1; M3: Month 3; M6: Month 6; M12: Month 12 of followupBack to article page